Enspryng

Roche autoimmune disease drug disappoints in closely watched trial
BioPharma Dive
Thu, 03/21/24 - 06:36 pm
Roche
Chugai
clinical trials
myasthenia gravis
Enspryng
New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
PM Live
Sat, 10/16/21 - 11:25 pm
Roche
Enspryng
NMOSD
Chugai’s Enspryng receives regulatory approval from FDA for neuromyelitis optica spectrum disorder
Pharmaceutical Business Review
Mon, 08/17/20 - 10:31 am
Chugai
FDA
Enspryng
NMOSD